Farallon Capital Management LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 2,250,400 shares of the biotechnology company's stock, valued at approximately $31,056,000. Farallon Capital Management LLC owned approximately 4.95% of Capricor Therapeutics at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. boosted its holdings in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after buying an additional 2,361 shares in the last quarter. Invesco Ltd. increased its holdings in Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after buying an additional 2,500 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. Finally, Corebridge Financial Inc. increased its holdings in Capricor Therapeutics by 32.2% in the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock valued at $251,000 after buying an additional 4,434 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Trading Up 12.1%
Shares of CAPR stock traded up $0.77 during trading hours on Monday, hitting $7.11. The company's stock had a trading volume of 3,522,000 shares, compared to its average volume of 1,621,087. The business has a fifty day moving average of $11.05 and a 200-day moving average of $14.03. The stock has a market cap of $324.76 million, a price-to-earnings ratio of -6.71 and a beta of 0.85. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. On average, equities analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
CAPR has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $34.50.
Read Our Latest Analysis on CAPR
Capricor Therapeutics Company Profile
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
